TRAW
NASDAQTraws Pharma Inc.
Price$0.68+0.01 (+1.28%)
03:30 PM05:30 PM
News · 26 weeks58+113%
2026-01-182026-07-12
Mix3790d
- SEC Filings19(51%)
- Insider11(30%)
- Other6(16%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Chief Science Officer Virology Pauza Charles David4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Director Cautreels Werner4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Savchuk Nikolay4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Director Stover Jack E4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Dukes Iain D.4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Redfield Robert4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Parker Charles Nolan4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Director Shoemaker Mary Teresa4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Director Clarke Trafford4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 4 filed by Director Leaman John Harold4 - Traws Pharma, Inc. (0001130598) (Issuer)
- SECTraws Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form 424B5 filed by Traws Pharma Inc.424B5 - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form EFFECT filed by Traws Pharma Inc.EFFECT - Traws Pharma, Inc. (0001130598) (Filer)
- SECTraws Pharma Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form S-3 filed by Traws Pharma Inc.S-3 - Traws Pharma, Inc. (0001130598) (Filer)
- SECTraws Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma Provides Updated Guidance on Influenza Prophylaxis ProgramNEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, Traws, the Company)), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that an updated toxicology data package is in the process of being developed in response to information requirements from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for the planned testing of tivoxavir marboxil (TXM) in a Phase 2a human influenza Challenge study. The updated data package is expected to be resubmitted to MHRA during the third quarter of 2026. "Based upon recent feedback and further guidance from the MHRA, we believe o
- ANALYSTTraws Pharma downgraded by Ladenburg ThalmannLadenburg Thalmann downgraded Traws Pharma from Buy to Neutral
- PRTraws Pharma Provides Regulatory Update on Influenza ProgramNEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, the Company)), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA). "Tivoxavir marboxil demonstrated potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile consistent with its use for bird flu treatment and prevention," said C. David Pauza, PhD Chief Science
- SECTraws Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form DEFA14A filed by Traws Pharma Inc.DEFA14A - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form DEF 14A filed by Traws Pharma Inc.DEF 14A - Traws Pharma, Inc. (0001130598) (Filer)
- SECTraws Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- PRTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease OutbreaksBroad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option to manage existing and future outbreaks Interactions planned with the US Centers for Disease Control and Prevention (CDC), and ongoing with the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC), and the African Medicines Agency (AMA) to fast-track clinical development, emergency manufacturing scale-up, and global access NEWTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW), a clinical-stage biopharmaceutical company d
- SECTraws Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
TRAW FAQ
6 questionsWhere does TRAW stock trade?
Traws Pharma Inc. (TRAW) is listed on NASDAQ.What sector and industry is TRAW in?
Traws Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Traws Pharma Inc. go public?
Traws Pharma Inc. (TRAW) completed its IPO in 2013.What are analysts saying about TRAW?
Traws Pharma Inc. has had 2 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Neutral on 2026-06-15. Recent price targets cluster around $800.00.What companies are similar to TRAW?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TRAW side-by-side with any of them on Quantisnow.How can I track TRAW on Quantisnow?
Quantisnow aggregates Traws Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRAW to receive live email and push alerts on every new disclosure.